We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Common Contracts

11 similar At Market Issuance Sales Agreement contracts by Evoke Pharma Inc, Galectin Therapeutics Inc, NephroGenex, Inc., others

GALECTIN THERAPEUTICS INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement
At Market Issuance Sales Agreement • May 19th, 2017 • Galectin Therapeutics Inc • Pharmaceutical preparations • New York

Galectin Therapeutics Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”), with FBR Capital Markets & Co. (“FBR”), as follows:

PSIVIDA CORP. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement
At Market Issuance Sales Agreement • February 8th, 2017 • pSivida Corp. • Laboratory analytical instruments • New York

pSivida Corp., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with FBR Capital Markets & Co. (“FBR”), as follows:

EVOKE PHARMA, INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales Agreement
At Market Issuance Sales Agreement • April 15th, 2016 • Evoke Pharma Inc • Pharmaceutical preparations • New York

Evoke Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with FBR Capital Markets & Co. (“FBR”), as follows:

NEPHROGENEX, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement
At Market Issuance Sales Agreement • August 7th, 2015 • NephroGenex, Inc. • Pharmaceutical preparations • New York

NephroGenex, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:

NEPHROGENEX, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement
At Market Issuance Sales Agreement • August 7th, 2015 • NephroGenex, Inc. • Pharmaceutical preparations • New York

NephroGenex, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:

AVEO PHARMACEUTICALS, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement
At Market Issuance Sales Agreement • February 27th, 2015 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations • New York

Aveo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:

EVOKE PHARMA, INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales Agreement
At Market Issuance Sales Agreement • November 13th, 2014 • Evoke Pharma Inc • Pharmaceutical preparations • New York

Evoke Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:

SORRENTO THERAPEUTICS, INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales Agreement
At Market Issuance Sales Agreement • November 4th, 2014 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • New York

Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:

CONATUS PHARMACEUTICALS INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales Agreement
At Market Issuance Sales Agreement • August 14th, 2014 • Conatus Pharmaceuticals Inc. • Pharmaceutical preparations • New York

Conatus Pharmaceuticals Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:

GALECTIN THERAPEUTICS INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement
At Market Issuance Sales Agreement • October 25th, 2013 • Galectin Therapeutics Inc • Pharmaceutical preparations • New York

Galectin Therapeutics Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:

CORONADO BIOSCIENCES, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement
At Market Issuance Sales Agreement • October 5th, 2012 • Coronado Biosciences Inc • Pharmaceutical preparations • New York

Coronado Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows: